These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date and reported results||2004-000327-15||A Phase 3 Multicenter, Open-label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) plus Leucovorin (LV) in Subjects with Advanced Biliary Tumors Not Amenable to Conventional Surgery||2006-12-06||bad-data|
|Ongoing||2008-002320-29||An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer||not-yet-due|
|Listed as ongoing, but also has a completion date||2009-012964-14||A randomized discontinuation study of XL184 in subjects with advanced solid tumors||2014-06-23||bad-data|
|Ongoing, reported early||2009-016707-30||A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma||not-yet-due|
|Exempt, with results||2009-016862-10||A Phase 1/2 Study of XL147 Administered in Combination with Trastuzumab or Paclitaxel and Trastuzumab in Subjects with Metastatic Breast Cancer who have Progressed on a Previous Trastuzumab- Based Reg...||not-yet-due|
|Listed as ongoing, but also has a completion date||2012-001426-99||A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer||2015-01-13||bad-data|
|Not reported||2012-001834-33||A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abi...||2015-05-25||due-trials|
|Ongoing||2013-001001-91||A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib.||not-yet-due|
|Ongoing||2013-001010-14||A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy||not-yet-due|
|Ongoing||2013-003402-40||A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients||not-yet-due|
|Other||2018-001771-21||A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Target...||not-yet-due|
|Ongoing||2018-003354-24||Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemi...||not-yet-due|